Plasminogen - 用于治疗慢性鼓膜穿孔的安全性:1 期随机、安慰剂对照研究。

IF 1.2 4区 医学 Q3 OTORHINOLARYNGOLOGY
Elnaz Sepehri,Bo Tideholm,Sten Hellström,Cecilia Engmér Berglin
{"title":"Plasminogen - 用于治疗慢性鼓膜穿孔的安全性:1 期随机、安慰剂对照研究。","authors":"Elnaz Sepehri,Bo Tideholm,Sten Hellström,Cecilia Engmér Berglin","doi":"10.1080/00016489.2024.2396488","DOIUrl":null,"url":null,"abstract":"BACKGROUND\r\nThere is a need for a simpler and accessible intervention to heal tympanic membrane perforations than myringoplasty that is todaýs golden standard. Experimental studies have identified plasminogen as a promising agent for medical treatment of chronic tympanic membrane perforation.\r\n\r\nAIMS/OBJECTIVES\r\nThis was a phase 1, prospective, randomized, placebo-controlled study with the main objective to evaluate the safety of injecting plasminogen in the vicinity of the tympanic membrane in subjects with chronic tympanic membrane perforation.\r\n\r\nMATERIAL AND METHODS\r\nAdults diagnosed with a dry chronic tympanic membrane perforation were recruited for an injection schedule with Human plasminogen 10. Adverse events, audiometry, VAS fluctuations and size of perforation, were monitored throughout the length of the study.\r\n\r\nRESULTS\r\nIt was possible to perform the injections according to schedule in all subjects. None of the subjects experienced any severe adverse events. Most common adverse event was ear pain. No signs of ototoxicity were reported.\r\n\r\nCONCLUSIONS AND SIGNIFICANCE\r\nThis pilot study suggests that plasminogen injections close to the tympanic membrane as treatment for chronic tympanic membrane injections are safe and feasible, encouraging further dose-escalating studies.","PeriodicalId":6880,"journal":{"name":"Acta Oto-Laryngologica","volume":"8 1","pages":"1-7"},"PeriodicalIF":1.2000,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Plasminogen - safe for treatment of chronic tympanic membrane perforation: a phase 1 randomized, placebo-controlled study.\",\"authors\":\"Elnaz Sepehri,Bo Tideholm,Sten Hellström,Cecilia Engmér Berglin\",\"doi\":\"10.1080/00016489.2024.2396488\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"BACKGROUND\\r\\nThere is a need for a simpler and accessible intervention to heal tympanic membrane perforations than myringoplasty that is todaýs golden standard. Experimental studies have identified plasminogen as a promising agent for medical treatment of chronic tympanic membrane perforation.\\r\\n\\r\\nAIMS/OBJECTIVES\\r\\nThis was a phase 1, prospective, randomized, placebo-controlled study with the main objective to evaluate the safety of injecting plasminogen in the vicinity of the tympanic membrane in subjects with chronic tympanic membrane perforation.\\r\\n\\r\\nMATERIAL AND METHODS\\r\\nAdults diagnosed with a dry chronic tympanic membrane perforation were recruited for an injection schedule with Human plasminogen 10. Adverse events, audiometry, VAS fluctuations and size of perforation, were monitored throughout the length of the study.\\r\\n\\r\\nRESULTS\\r\\nIt was possible to perform the injections according to schedule in all subjects. None of the subjects experienced any severe adverse events. Most common adverse event was ear pain. No signs of ototoxicity were reported.\\r\\n\\r\\nCONCLUSIONS AND SIGNIFICANCE\\r\\nThis pilot study suggests that plasminogen injections close to the tympanic membrane as treatment for chronic tympanic membrane injections are safe and feasible, encouraging further dose-escalating studies.\",\"PeriodicalId\":6880,\"journal\":{\"name\":\"Acta Oto-Laryngologica\",\"volume\":\"8 1\",\"pages\":\"1-7\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2024-09-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta Oto-Laryngologica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/00016489.2024.2396488\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"OTORHINOLARYNGOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Oto-Laryngologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/00016489.2024.2396488","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景与鼓膜成形术相比,鼓膜穿孔的愈合需要一种更简单易行的干预方法,而鼓膜成形术是目前的黄金标准。实验研究发现,纤溶酶原是治疗慢性鼓膜穿孔的一种有前景的药物。目的/目标这是一项 1 期、前瞻性、随机、安慰剂对照研究,主要目的是评估在慢性鼓膜穿孔患者的鼓膜附近注射纤溶酶原的安全性。结果所有受试者都能按计划进行注射。所有受试者均未出现严重不良反应。最常见的不良反应是耳痛。结论和意义这项试验性研究表明,在鼓膜附近注射纤溶酶原治疗慢性鼓膜穿孔是安全可行的,因此鼓励进一步进行剂量递增研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Plasminogen - safe for treatment of chronic tympanic membrane perforation: a phase 1 randomized, placebo-controlled study.
BACKGROUND There is a need for a simpler and accessible intervention to heal tympanic membrane perforations than myringoplasty that is todaýs golden standard. Experimental studies have identified plasminogen as a promising agent for medical treatment of chronic tympanic membrane perforation. AIMS/OBJECTIVES This was a phase 1, prospective, randomized, placebo-controlled study with the main objective to evaluate the safety of injecting plasminogen in the vicinity of the tympanic membrane in subjects with chronic tympanic membrane perforation. MATERIAL AND METHODS Adults diagnosed with a dry chronic tympanic membrane perforation were recruited for an injection schedule with Human plasminogen 10. Adverse events, audiometry, VAS fluctuations and size of perforation, were monitored throughout the length of the study. RESULTS It was possible to perform the injections according to schedule in all subjects. None of the subjects experienced any severe adverse events. Most common adverse event was ear pain. No signs of ototoxicity were reported. CONCLUSIONS AND SIGNIFICANCE This pilot study suggests that plasminogen injections close to the tympanic membrane as treatment for chronic tympanic membrane injections are safe and feasible, encouraging further dose-escalating studies.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Acta Oto-Laryngologica
Acta Oto-Laryngologica 医学-耳鼻喉科学
CiteScore
2.50
自引率
0.00%
发文量
99
审稿时长
3-6 weeks
期刊介绍: Acta Oto-Laryngologica is a truly international journal for translational otolaryngology and head- and neck surgery. The journal presents cutting-edge papers on clinical practice, clinical research and basic sciences. Acta also bridges the gap between clinical and basic research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信